A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumours shows early promise for delivering similar benefits to patients with difficult-to-treat meningioma, a type of brain tumour.

Findings of the non-randomised phase II study will be presented today at the American Society for Radiation Oncology (ASTRO) Annual Meeting .

“We’ve found a therapy with a meaningful signal for effectiveness and safety for people with refractory meningioma, a condition with no standard treatment options,” said Kenneth W.Merrell, MD, principal investigator (PI) of the trial and a radiation oncologist at the Mayo Clinic Alix School of Medicine in Rochester, Minn.

“Nearly 80% of patients in our study were progression-free after six months. This rate greatly surpassed the benchmark from prior research, suggesting that radiopharmaceuticals are a promising therapeutic agent for these patients.”

Meningiomas are tumours that grow in the connective tissue surrounding the brain and spinal cord.

They are the most common type of primary brain tumour, and while they typically do not spread to other parts of the body, they can grow uncontrollably and lead to disabling and deadly compression of the nerves and brain.

Standard treatment for patients with meningiomas is either surgical removal or external beam radiation therapy when tumours grow in areas where surgery is too dangerous, such as close to the brain stem or spinal cord.

But for the portion of patients where the tumour grows despite these treatments, known as refractory meningioma, the tumours tend to behave more aggressively, and retreatment is difficult because radiation and surgery cannot be repeated frequently without greater risks.

“There is no standard of care or proven option for managing refractory meningioma. Many of these patients continue to experience aggressive tumour growth and significant related complications, and ultimately the illness may prove fatal. It is a very challenging prognosis to manage, and in many cases, we are left with only supportive measures,” Dr. Merrell said.

Dr. Merrell and his colleagues investigated whether patients with refractory meningioma would benefit from theranostics, an approach that combines therapy with diagnostics for personalised internal delivery of radiation treatment.

Theranostics leverages radiopharmaceuticals — specialised medicine containing radioactive material — to find cancer cells in the body and attack them with precise doses of radiation, without harming the surrounding healthy tissue.

This dual-pronged approach offers patients a more tailored, and potentially more effective, treatment option.

While still an emerging treatment modality, radiopharmaceuticals are commonly used to treat thyroid cancer, metastatic cancer such as bone metastases from prostate cancer, and other types of tumours.

For this trial, researchers looked specifically at ¹⁷⁷ Lu-Dotatate, an FDA-approved radiopharmaceutical for neuroendocrine tumours, which share biological similarities with meningiomas.

“There have been many attempts at testing a variety of chemotherapies and other systemic agents for these patients. And others have looked at this option for therapy, but no one had completed a prospective trial for this patient population before ours,” said Geoffrey B.Johnson, MD, PhD, the co-PI of the trial and a nuclear medicine physician at the Mayo Clinic.

“With advanced PET imaging, the theranostic approach to treatment helps us to select those patients most likely to benefit from molecularly targeted radiation directly to their tumour cells.”

The researchers conducted a single-arm, phase II clinical trial at a large academic center, enrolling patients with refractory meningioma that had grown at a rate of 15% or more over a six-month period.

During a three-year period beginning in April 2020, patients including 20 people with WHO grade 2 or 3 disease were enrolled into the study.

The median patient age was 67, and nearly all (95%) had grade 2 meningiomas.

Trial participants received four infusions of ¹⁷⁷Lu-Dotatate spaced eight weeks apart.

Six months after treatment, 78% of patients had not experienced further tumour progression, far exceeding the benchmark progression-free survival rate of 26% established by prior research.

The median time before patients' cancer progressed was 11.5 months. After one year, overall survival was 88.9%.

No patients experienced life-threatening side effects, while 10 had severely low blood counts, one had grade 3 hepatitis and one had a grade 3 seizure possibly related to treatment.

Five patients did not complete treatment due to tumour progression (n=2), adverse events possibly related to treatment (n=2) or other comorbidities (n-1).comorbidities (n-1).

“Most patients tolerated the treatment well,” Dr. Merrell said. “It appears that ¹⁷⁷ Lu-Dotatate is a safe and rational therapeutic choice with broad eligibility for patients with aggressively growing meningiomas, particularly as alternative therapy options are limited.”

“As there is no current standard of care for these patients, our findings establish a new benchmark and may influence the treatment options available.”

Source: American Society for Radiation Oncology